

From: $994.00
The Sulfated Glycan Array provides researchers with a powerful tool to study the interactions between sulfated glycans and a wide range of biological samples, such as proteins, antibodies, cell lysates, serum, vesicles, bacteria, or viral particles. This innovative array features 46 structurally-defined glycans, including paired sulfated glycans and their non-sulfated counterparts. The glycan repertoire includes diverse types such as O-glycans, O-mannose glycans, and various small glycan motifs, offering a comprehensive platform for sulfated glycan-binding studies.
Each array is equipped with 8 or 16 identical subarrays, enabling the simultaneous analysis of multiple samples. Results can be generated within hours, facilitating quick and efficient exploration of sulfated glycan interactions. Assay services are available upon request to support your experimental goals.
Introduction
Sulfated glycans are a distinct class of sugar molecules characterized by the addition of sulfate groups to their structures. These modifications play crucial roles in a variety of biological processes, including cellular communication, immune response, and the regulation of signaling pathways. Sulfated glycans are especially known for their ability to mediate interactions with proteins, such as lectins and growth factors, influencing key physiological and pathological processes. For instance, sulfated glycans have been implicated in modulating inflammation, inhibiting viral entry, and regulating tumor progression.
The biological activities of sulfated glycans are often linked to their specific structural motifs, which include the arrangement of monosaccharides, linkage types, and sulfate group positions. These motifs determine the binding affinity and specificity of sulfated glycans toward various biological targets. Due to their importance, sulfated glycans have been investigated as biomarkers for diseases and as therapeutic targets for drug development. Moreover, paired comparisons of sulfated glycans with their non-sulfated forms provide valuable insights into the functional roles of sulfation in glycan activity.
ZBiotech has developed a robust Sulfated Glycan Array to explore the interactions between sulfated glycans and various biological samples, such as proteins, antibodies, cells, cell lysates, serum, vesicles, bacteria, or viral particles. The array features 46 structurally-defined glycans, including paired sulfated glycans and their non-sulfated counterparts. Each slide contains 8 or 16 identical subarrays, allowing for the simultaneous analysis of multiple samples. Results can be obtained in just a few hours, making the study of glycan-binding interactions efficient and accessible. The Sulfated Glycan Array delivers high-throughput, reliable data and can be customized to meet specific research needs. Assay services are also available upon request.
Handling and Storage
Store the bag of slides and any buffers in a 4°C refrigerator if they are to be assayed within 3 weeks upon receipt. For long term storage keep the bag of slides at -20°C. Avoid freezing and thawing multiple times. Purchased slides and buffers should be used within 6 months.
Allow the bag of slides to equilibrate to room temperature at least 20 minutes before opening. After opening, re-seal any unused slides in the moisture barrier bag with a desiccant inside and refreeze.
Array Map/Schematic
Glycosaminoglycan Microarray slides have either 8 or 16 subarrays. Arrays are printed on the side with the “Z Biotech” label and 4-digit number ID facing upward. The “Z Biotech” label is located on the bottom center from a landscape view. The number ID is consistent with the barcode ID on the bottom from a portrait view. Dimensions and array maps are shown below.



Controls


Controls
Sulfated Glycan Array SNFG Structures:

| ID | Structure |
|---|---|
| S1 | Galβ1-4Glcβ |
| S2 | (3S)Galβ1-4Glcβ |
| S3 | Galβ1-4GlcNAcβ |
| S4 | Galβ1-4(6S)GlcNAcβ |
| S5 | (6S)Galβ1-4GlcNAcβ |
| S6 | Galβ1-3(Fucα1-4)GlcNAcβ |
| S7 | (3S)Galβ1-3(Fucα1-4)GlcNAcβ |
| S8 | Galβ1-4(Fucα1-3)GlcNAcβ |
| S9 | (3S)Galβ1-4(Fucα1-3)GlcNAcβ |
| S10 | Neu5Acα2-3Galβ1-4GlcNAcβ |
| S11 | Neu5Acα2-3Galβ1-4(6S)GlcNAcβ |
| S12 | Neu5Acα2-3(6S)Galβ1-4GlcNAcβ |
| S13 | Neu5Acα2-3(6S)Galβ1-4(6S)GlcNAcβ |
| S14 | Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ |
| S15 | Neu5Acα2-3(6S)Galβ1-4(Fucα1-3)GlcNAc |
| S16 | GlcNAcβ1-6(Galβ1-4GlcNAcβ1-2)Manα |
| S17 | (6S)GlcNAcβ1-6(Galβ1-4GlcNAcβ1-2)Manα |
| S18 | GlcNAcβ1-6(Neu5Acα2-6Galβ1-4GlcNAcβ1-2)Manα |
| S19 | (6S)GlcNAcβ1-6(Neu5Acα2-6Galβ1-4GlcNAcβ1-2)Manα |
| S20 | Galβ1-4GlcNAcβ1-6(Neu5Acα2-6Galβ1-4GlcNAcβ1-2)Manα |
| S21 | Galβ1-4(6S)GlcNAcβ1-6(Neu5Acα2-6Galβ1-4GlcNAcβ1-2)Manα |
| S22 | Neu5Acα2-6Galβ1-4GlcNAcβ1-6(Neu5Acα2-6Galβ1-4GlcNAcβ1-2)Manα |
| S23 | Neu5Acα2-6Galβ1-4(6S)GlcNAcβ1-6(Neu5Acα2-6Galβ1-4GlcNAcβ1-2)Manα |
| S24 | Galβ1-4(Fucα1-3)GlcNAcβ1-6(Neu5Acα2-6Galβ1-4GlcNAcβ1-2)Manα |
| S25 | Galβ1-4(Fucα1-3)(6S)GlcNAcβ1-6(Neu5Acα2-6Galβ1-4GlcNAcβ1-2)Manα |
| S26 | Galβ1-4(Fucα1-3)GlcNAcβ1-6(Galβ1-4GlcNAcβ1-2)Manα |
| S27 | Galβ1-4(Fucα1-3)(6S)GlcNAcβ1-6(Galβ1-4GlcNAcβ1-2)Manα |
| S28 | GlcNAcβ1-6(Galβ1-3)GalNAcα |
| S29 | (6S)GlcNAcβ1-6(Galβ1-3)GalNAcα |
| S30 | GlcNAcβ1-6(Neu5Acα2-3Galβ1-3)GalNAcα |
| S31 | (6S)GlcNAcβ1-6(Neu5Acα2-3Galβ1-3)GalNAcα |
| S32 | (6S)GlcNAcβ1-6(GlcNAcβ1-3Galβ1-3)GalNAcα |
| S33 | Galβ1-4(6S)GlcNAcβ1-6(Galβ1-4GlcNAcβ1-3Galβ1-3)GalNAcα |
| S34 | Neu5Acα2-3Galβ1-4(6S)GlcNAcβ1-6(Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-3)GalNAcα |
| S35 | Neu5Acα2-3Galβ1-4(Fucα1-3)(6S)GlcNAcβ1-6(Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3)GalNAcα |
| S36 | (6S)GlcNAcβ1-6((6S)GlcNAcβ1-3Galβ1-3)GalNAcα |
| S37 | Galβ1-4(6S)GlcNAcβ1-6(Galβ1-4(6S)GlcNAcβ1-3Galβ1-3)GalNAcα |
| S38 | Neu5Acα2-3Galβ1-4(6S)GlcNAcβ1-6(Neu5Acα2-3Galβ1-4(6S)GlcNAcβ1-3Galβ1-3)GalNAcα |
| S39 | Galβ1-4(Fucα1-3)(6S)GlcNAcβ1-6(Galβ1-4(Fucα1-3)(6S)GlcNAcβ1-3Galβ1-3)GalNAcα |
| S40 | Galβ1-4GlcNAcβ1-6(Neu5Acα2-3Galβ1-3)GalNAcα |
| S41 | Galβ1-4(6S)GlcNAcβ1-6(Neu5Acα2-3Galβ1-3)GalNAcα |
| S42 | Neu5Acα2-3Galβ1-4GlcNAcβ1-6(Neu5Acα2-3Galβ1-3)GalNAcα |
| S43 | Neu5Acα2-3Galβ1-4(6S)GlcNAcβ1-6(Neu5Acα2-3Galβ1-3)GalNAcα |
| S44 | Neu5Acα2-6Galβ1-4(6S)GlcNAcβ1-6(Neu5Acα2-3Galβ1-3)GalNAcα |
| S45 | Neu5Acα2-3Galβ1-4(Fucα1-3)(6S)GlcNAcβ1-6(Neu5Acα2-3Galβ1-3)GalNAcα |
| S46 | Neu5Acα2-3Galβ1-4(Fucα1-3)(6S)GlcNAcβ1-6(Neu5Acα2-3Galβ1-4(Fucα1-3)(6S)GlcNAcβ1-3Galβ1-3)GalNAcα |
Controls
Materials Required
Preparation of assay samples:
Prepare glycan-binding protein samples or secondary antibodies of interest in a centrifuge tube by diluting with the Glycan Array Assay Buffer. We recommend a range of 50 μg/ml to 0.1 μg/ml concentration for protein samples, although some experimentation may be required to establish the concentration that will provide the highest binding signals with the lowest background fluorescence. This is often accomplished by applying a different dilution of samples to different wells of the array. For the fluorescently labelled streptavidin we recommend a concentration of 1 μg/mL. Calculate the volume of sample needed depending on how many slides and subarrays are to be assayed. We recommend using 100 μL volume of sample per well for 16 subarray cassettes and 200 μL for 8 subarray cassettes to ensure full and even coverage of the printed area throughout incubation for every step of the assay . If necessary, the assay can be done successfully with a minimal volume of 60 μL per well for 16 subarray cassettes and 80 μL for 8 subarray cassettes. We caution that using a minimal volume in the wells has an increased risk of the array drying out during the assay and may also cause unequal distribution of the sample across the arrayed surface which may result in signal variation. Please ensure each sample is homogeneous and thoroughly mixed.
Assay Protocol
Considerations Before Starting the Experiment
1. Preparation of Buffers:
2. BSA Addition:
3. Avoiding Dryness:
4. Array Formats and Volumes:
5. Sample Preparation:
6. Storage of Microarray Slides and Buffers:
Analyzing Biological Samples with Glycan Microarray
Part 1: Blocking
Handle the slide in a clean, dry environment. Use gloves and avoid touching the slide surface.
1. Let the microarray slide equilibrate to room temperature (20-30 minutes) before opening the moisture barrier bag.
2. Assemble the slide into a hybridization chamber device.
3. Add the Glycan Array Blocking Buffer (GABB) to each subarray well of the assembled hybridization chamber device:
4. Cover the hybridization chamber device with adhesive film to prevent evaporation and incubate the slide on a shaker at 80 rpm for 30 minutes. Ensure the orbital shaker is completely flat to avoid variations in binding and detection. Longer incubation times are acceptable but not necessary.
5. After 30 minutes, add 100 μL of Glycan Array Assay Buffer (GAAB) to each subarray well of a 16-subarray chamber device (or 200 μL of GAAB to each subarray well of an 8-subarray chamber device). Aspirate the liquid out from each well, ensuring that some liquid remains to cover the surface.
6. Add another 100 μL of GAAB to each subarray well of a 16-subarray chamber device (or 200 μL of GAAB to each subarray well of an 8-subarray chamber device). Incubate at room temperature for 5 minutes at 80 rpm on a shaker.
7. After incubation, aspirate all the liquid out from each well. Then add 100 μL of GAAB to each subarray well of a 16-subarray chamber device (or 200 μL of GAAB to each subarray well of an 8-subarray chamber device). Incubate at room temperature for 5 minutes at 80 rpm on a shaker.
8. After incubation, aspirate all the liquid out from each well. Then add 100 μL of GAAB to each subarray well of a 16-subarray chamber device (or 200 μL of GAAB to each subarray well of an 8-subarray chamber device). Incubate at room temperature for 5 minutes at 80 rpm on a shaker.
Part 2: Binding Assay
1.Unless the glycan-binding protein sample of interest is bacteria or cells, centrifuge samples briefly to avoid adding irrelevant particles to the array.
2.Remove the blocking buffer from each well by gently touching a pipette tip to the corner of the well. We recommend doing this one subarray at a time, not handling multiple subarrays simultaneously to avoid drying out the microarray slide surface.
3.Immediately apply the glycan-binding protein sample of interest to each well.
4.Seal the wells with adhesive film to prevent evaporation. If the sample is fluorescently labeled, cover it with aluminum foil to keep it in the dark.
5.Incubate on the shaker for 1 hour at 80 rpm. Longer incubation times may increase the binding signal, especially for weakly binding samples. Avoid allowing the slides to dry out at any point during the assay, especially during long incubation times. Make sure the adhesive film is sealed around each well.
6.If your glycan-binding protein samples are fluorescently labeled, go directly to Part 6 – Final Wash and Dry.
Part 3: Wash
We recommend doing the following procedure using a multi-channel pipette.
1. Initial Wash:
2. Subsequent Washes:
3. Final Wash:
4. Proceed to the Next Step:
Part 4: Binding of Biotinylated Antibody (Sandwich Assay Format)
1. Adding Secondary Antibody:
2. Incubation:
Part 5: Fluorescent Staining
1. Adding Streptavidin:
2.Incubation:
Part 6: Final Wash and Dry
1. Initial Wash:
2. Subsequent Washes:
3. Final Wash:
4. Disassembling the Hybridization Chamber:
5.Immersing the Slide:
6. Rinsing with Water:
7. Repeat Rinsing:
8. Drying the Slide:
Part 7: Data Acquisition and Analysis
1. Scanning the Slide:
2. Analyzing Data:
3. Quantifying Signal Intensities:
4. Interpreting Control Signals:
Typical Binding Assay Result from the Sulfated Glycan Microarray
Example 1: Aleuria aurantia lectin (AAL) binds to various sulfated and non-sulfated glycans that contain fucose.
The Sulfated Glycan Array was tested using biotinylated AAL lectin (5 μg/mL), followed by streptavidin-Cy3 (0.2 μg/mL). The array was scanned with a microarray scanner at a wavelength of 532 nm, and the positive controls demonstrated binding signals as expected. AAL exhibited binding to multiple sulfated and non-sulfated glycans with fucose present.

Example 2: Human Siglec-8 and Its Interaction with Sulfated Glycans
Human Siglec-8, a sialic acid-binding immunoglobulin-like lectin, is predominantly expressed on eosinophils and mast cells and plays a significant role in regulating immune responses. It is known to bind selectively to specific glycans, particularly sulfated glycans such as 6′-sulfo-sLex, which contribute to its functional specificity in various physiological and pathological processes, including inflammation and allergy regulation.
The Sulfated Glycan Array was used to investigate the binding interactions of human Siglec-8. The assay utilized the extracellular binding domain of human Siglec-8 fused to an human IgG Fc tag (2.5 μg/mL), followed by detection with anti-human IgG Fc (2.5 μg/mL). Scanning at a wavelength of 532 nm revealed binding signals. Human Siglec-8 exhibited binding to multiple sulfated glycans.

Troubleshooting
| Condition | Possible Causes | Potential Solutions |
|---|---|---|
| High Background |
|
|
| Signal Variation |
|
|
| Unexpected Binding |
|
|
List of Sulfated glycan structures on the array (download the PDF)
Protocol & User Manual (download the manual)


